A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

Summary

For Safety introduction phase，this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II dose (RP2D). For Dose expansion phase，this study is to evaluate the preliminary antitumor activity of LM-168 in combination with other antitumor treatment regimens in participants of advanced solid tumor trials, measured by objective response rate (ORR)

Timeline

Start

2026-06-30

Primary completion

2027-12-15

Completion

2028-12-15

Drugs

Indications